Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546583 · ClinicalTrials.gov registry record · Phase 1
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 458
- Enrollment target
NCT02546583 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 458 participants.
The verdict
NCT02546583, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 458 participants
- Enrollment target
Study Summary
Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using currently available methods, leading to trial-and-error based treatment that promotes lengthy hospitalizations. The aims of this study are: 1. To develop inexpensive and efficient tools to predict diuretic response 2. To understand the prevalence of therapeutically targetable mechanisms of diuretic resistance using endogenous lithium clearance 3. To develop methodology to differentiate diuretic resistance mechanisms using common/inexpensive laboratory tests 4. To provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis
Interventions
- DRUG Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)
- DRUG IV Chlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2020-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02546583
The ClinicalTrials.gov registry entry for NCT02546583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) is the first listed.
NCT02546583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02546583 about?
NCT02546583 is a clinical study titled "Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure". Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using cu...
What is the current status of trial NCT02546583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 458 participants. The study started on 2015-08-31. Estimated completion is 2020-01-23.
What interventions are being tested in trial NCT02546583?
The interventions under investigation include: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) (DRUG), IV Chlorothiazide (DRUG).
Who is sponsoring clinical trial NCT02546583?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.